CT-SPECT fusion plus conjugate views for determining dosimetry in iodine- 131-monoclonal antibody therapy of lymphoma patients

K. F. Koral, K. R. Zasadny, M. L. Kessler, J. Q. Luo, S. F. Buchbinder, M. S. Kaminski, I. Francis, R. L. Wahl

Research output: Contribution to journalArticle

Abstract

A method for performing 131I quantitative SPECT imaging is described which uses the superimposition of markers placed on the skin to accomplish fusion of computed tomography (CT) and SPECT image sets. Methods: To calculate mean absorbed dose after administration of one of two 131I- labeled monoclonal antibodies (Mabs), the shape of the time-activity curve is measured by daily diagnostic conjugate views, the y-axis of that curve is normalized by a quantitative SPECT measurement (usually intra-therapy), and the tumor mass is deduced from a concurrent CT volume measurement. The method is applied to six B-cell non-Hodgkin's lymphoma patients. Results: For four tumors in three patients treated with the MB1 Mab, a correlation appears to be present between resulting mean absorbed dose and disease response. Including all dosimetric estimates for both antibodies, the range for the specific absorbed dose is within that found by others in treating B-cell lymphoma patients. Excluding a retreated anti-B1 patient, the tumor-specific absorbed dose during anti-B1 therapy is from 1.4 to 1.7 mGy/MBq. For the one anti-B1 patient, where quantitative SPECT and conjugate-view imaging was carried out back to back, the quantitative SPECT-measured activity was somewhat less for the spleen and much less for the tumor than that from conjugate views. Conclusion: The quantitative SPECT plus conjugate views method may be of general utility for macro-dosimetry of 131I therapies.

Original languageEnglish (US)
Pages (from-to)1714-1720
Number of pages7
JournalJournal of Nuclear Medicine
Volume35
Issue number10
StatePublished - 1994
Externally publishedYes

Fingerprint

Single-Photon Emission-Computed Tomography
Iodine
Lymphoma
Monoclonal Antibodies
Tomography
B-Cell Lymphoma
Neoplasms
Therapeutics
Cone-Beam Computed Tomography
Non-Hodgkin's Lymphoma
Spleen
Skin
Antibodies

Keywords

  • conjugate views
  • iodine-131
  • lymphoma
  • radioimmunotherapy
  • SPECT

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Koral, K. F., Zasadny, K. R., Kessler, M. L., Luo, J. Q., Buchbinder, S. F., Kaminski, M. S., ... Wahl, R. L. (1994). CT-SPECT fusion plus conjugate views for determining dosimetry in iodine- 131-monoclonal antibody therapy of lymphoma patients. Journal of Nuclear Medicine, 35(10), 1714-1720.

CT-SPECT fusion plus conjugate views for determining dosimetry in iodine- 131-monoclonal antibody therapy of lymphoma patients. / Koral, K. F.; Zasadny, K. R.; Kessler, M. L.; Luo, J. Q.; Buchbinder, S. F.; Kaminski, M. S.; Francis, I.; Wahl, R. L.

In: Journal of Nuclear Medicine, Vol. 35, No. 10, 1994, p. 1714-1720.

Research output: Contribution to journalArticle

Koral, KF, Zasadny, KR, Kessler, ML, Luo, JQ, Buchbinder, SF, Kaminski, MS, Francis, I & Wahl, RL 1994, 'CT-SPECT fusion plus conjugate views for determining dosimetry in iodine- 131-monoclonal antibody therapy of lymphoma patients', Journal of Nuclear Medicine, vol. 35, no. 10, pp. 1714-1720.
Koral KF, Zasadny KR, Kessler ML, Luo JQ, Buchbinder SF, Kaminski MS et al. CT-SPECT fusion plus conjugate views for determining dosimetry in iodine- 131-monoclonal antibody therapy of lymphoma patients. Journal of Nuclear Medicine. 1994;35(10):1714-1720.
Koral, K. F. ; Zasadny, K. R. ; Kessler, M. L. ; Luo, J. Q. ; Buchbinder, S. F. ; Kaminski, M. S. ; Francis, I. ; Wahl, R. L. / CT-SPECT fusion plus conjugate views for determining dosimetry in iodine- 131-monoclonal antibody therapy of lymphoma patients. In: Journal of Nuclear Medicine. 1994 ; Vol. 35, No. 10. pp. 1714-1720.
@article{57c0b5b349e74b43a736a6c0841ff1c2,
title = "CT-SPECT fusion plus conjugate views for determining dosimetry in iodine- 131-monoclonal antibody therapy of lymphoma patients",
abstract = "A method for performing 131I quantitative SPECT imaging is described which uses the superimposition of markers placed on the skin to accomplish fusion of computed tomography (CT) and SPECT image sets. Methods: To calculate mean absorbed dose after administration of one of two 131I- labeled monoclonal antibodies (Mabs), the shape of the time-activity curve is measured by daily diagnostic conjugate views, the y-axis of that curve is normalized by a quantitative SPECT measurement (usually intra-therapy), and the tumor mass is deduced from a concurrent CT volume measurement. The method is applied to six B-cell non-Hodgkin's lymphoma patients. Results: For four tumors in three patients treated with the MB1 Mab, a correlation appears to be present between resulting mean absorbed dose and disease response. Including all dosimetric estimates for both antibodies, the range for the specific absorbed dose is within that found by others in treating B-cell lymphoma patients. Excluding a retreated anti-B1 patient, the tumor-specific absorbed dose during anti-B1 therapy is from 1.4 to 1.7 mGy/MBq. For the one anti-B1 patient, where quantitative SPECT and conjugate-view imaging was carried out back to back, the quantitative SPECT-measured activity was somewhat less for the spleen and much less for the tumor than that from conjugate views. Conclusion: The quantitative SPECT plus conjugate views method may be of general utility for macro-dosimetry of 131I therapies.",
keywords = "conjugate views, iodine-131, lymphoma, radioimmunotherapy, SPECT",
author = "Koral, {K. F.} and Zasadny, {K. R.} and Kessler, {M. L.} and Luo, {J. Q.} and Buchbinder, {S. F.} and Kaminski, {M. S.} and I. Francis and Wahl, {R. L.}",
year = "1994",
language = "English (US)",
volume = "35",
pages = "1714--1720",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "10",

}

TY - JOUR

T1 - CT-SPECT fusion plus conjugate views for determining dosimetry in iodine- 131-monoclonal antibody therapy of lymphoma patients

AU - Koral, K. F.

AU - Zasadny, K. R.

AU - Kessler, M. L.

AU - Luo, J. Q.

AU - Buchbinder, S. F.

AU - Kaminski, M. S.

AU - Francis, I.

AU - Wahl, R. L.

PY - 1994

Y1 - 1994

N2 - A method for performing 131I quantitative SPECT imaging is described which uses the superimposition of markers placed on the skin to accomplish fusion of computed tomography (CT) and SPECT image sets. Methods: To calculate mean absorbed dose after administration of one of two 131I- labeled monoclonal antibodies (Mabs), the shape of the time-activity curve is measured by daily diagnostic conjugate views, the y-axis of that curve is normalized by a quantitative SPECT measurement (usually intra-therapy), and the tumor mass is deduced from a concurrent CT volume measurement. The method is applied to six B-cell non-Hodgkin's lymphoma patients. Results: For four tumors in three patients treated with the MB1 Mab, a correlation appears to be present between resulting mean absorbed dose and disease response. Including all dosimetric estimates for both antibodies, the range for the specific absorbed dose is within that found by others in treating B-cell lymphoma patients. Excluding a retreated anti-B1 patient, the tumor-specific absorbed dose during anti-B1 therapy is from 1.4 to 1.7 mGy/MBq. For the one anti-B1 patient, where quantitative SPECT and conjugate-view imaging was carried out back to back, the quantitative SPECT-measured activity was somewhat less for the spleen and much less for the tumor than that from conjugate views. Conclusion: The quantitative SPECT plus conjugate views method may be of general utility for macro-dosimetry of 131I therapies.

AB - A method for performing 131I quantitative SPECT imaging is described which uses the superimposition of markers placed on the skin to accomplish fusion of computed tomography (CT) and SPECT image sets. Methods: To calculate mean absorbed dose after administration of one of two 131I- labeled monoclonal antibodies (Mabs), the shape of the time-activity curve is measured by daily diagnostic conjugate views, the y-axis of that curve is normalized by a quantitative SPECT measurement (usually intra-therapy), and the tumor mass is deduced from a concurrent CT volume measurement. The method is applied to six B-cell non-Hodgkin's lymphoma patients. Results: For four tumors in three patients treated with the MB1 Mab, a correlation appears to be present between resulting mean absorbed dose and disease response. Including all dosimetric estimates for both antibodies, the range for the specific absorbed dose is within that found by others in treating B-cell lymphoma patients. Excluding a retreated anti-B1 patient, the tumor-specific absorbed dose during anti-B1 therapy is from 1.4 to 1.7 mGy/MBq. For the one anti-B1 patient, where quantitative SPECT and conjugate-view imaging was carried out back to back, the quantitative SPECT-measured activity was somewhat less for the spleen and much less for the tumor than that from conjugate views. Conclusion: The quantitative SPECT plus conjugate views method may be of general utility for macro-dosimetry of 131I therapies.

KW - conjugate views

KW - iodine-131

KW - lymphoma

KW - radioimmunotherapy

KW - SPECT

UR - http://www.scopus.com/inward/record.url?scp=0028136461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028136461&partnerID=8YFLogxK

M3 - Article

VL - 35

SP - 1714

EP - 1720

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 10

ER -